A
Alan J. Thomas
Researcher at Newcastle University
Publications - 294
Citations - 13273
Alan J. Thomas is an academic researcher from Newcastle University. The author has contributed to research in topics: Dementia & Dementia with Lewy bodies. The author has an hindex of 55, co-authored 270 publications receiving 10165 citations. Previous affiliations of Alan J. Thomas include Newcastle upon Tyne Hospitals NHS Foundation Trust & Northumberland, Tyne and Wear NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Common and distinct patterns of grey-matter volume alteration in major depression and bipolar disorder: evidence from voxel-based meta-analysis
Toby Wise,Joaquim Radua,Joaquim Radua,Esther Via,Narcís Cardoner,Osamu Abe,Tracey M. Adams,Francesco Amico,Yuqi Cheng,James H. Cole,C De Azevedo Marques Périco,Daniel P. Dickstein,Tom F.D. Farrow,Thomas Frodl,Thomas Frodl,Gregory R. Wagner,Ian H. Gotlib,Oliver Gruber,Byung Joo Ham,Dominic Job,Matthew J. Kempton,M J Kim,P C M P Koolschijn,Gin S Malhi,David Mataix-Cols,David Mataix-Cols,Andrew M. McIntosh,Allison C. Nugent,John T. O'Brien,John T. O'Brien,Stefania Pezzoli,Stefania Pezzoli,Mary L. Phillips,Perminder S. Sachdev,Giacomo Salvadore,Sudhakar Selvaraj,Andrew C. Stanfield,Alan J. Thomas,M.J.D. van Tol,N.J.A. van der Wee,Dick J. Veltman,Archie Young,Cynthia H.Y. Fu,Cynthia H.Y. Fu,Anthony J. Cleare,Danilo Arnone +45 more
TL;DR: The results suggest that MDD and BD are characterised by both common and distinct patterns of grey-matter volume changes, which has the potential to inform the development of diagnostic biomarkers for these conditions.
Journal ArticleDOI
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial
Sube Banerjee,Jennifer Hellier,Michael E. Dewey,Renee Romeo,Clive Ballard,Robert Baldwin,Peter Bentham,Chris Fox,Clive Holmes,Cornelius Katona,Martin Knapp,Claire Lawton,James Lindesay,Gill Livingston,Niall McCrae,Esme Moniz-Cook,Joanna Murray,Shirley Nurock,Martin Orrell,John T. O'Brien,Michaela Poppe,Alan J. Thomas,Rebecca Walwyn,Kenneth Wilson,Alistair Burns +24 more
TL;DR: Because of the absence of benefit compared with placebo and increased risk of adverse events, the present practice of use of these antidepressants, with usual care, for first-line treatment of depression in Alzheimer's disease should be reconsidered.
Journal ArticleDOI
Ischemic basis for deep white matter hyperintensities in major depression: a neuropathological study.
Alan J. Thomas,John T. O'Brien,Sue Davis,Clive Ballard,Robert Barber,Rajesh N. Kalaria,Robert H. Perry +6 more
TL;DR: In this article, the authors investigated the neuropathological basis of these lesions in depression, hypothesizing that they would be more frequently ischemic in origin in depressed subjects, and found that deep white matter hyperintensities are more frequently due to cerebral ischemia.
Journal ArticleDOI
Depression and dementia: Cause, consequence or coincidence?
Sophia Bennett,Alan J. Thomas +1 more
TL;DR: Overall there is convincing evidence to support both the notion that early life depression can act as a risk factor for later life dementia, and that laterlife depression can be seen as a prodrome to dementia.
Journal ArticleDOI
Research criteria for the diagnosis of prodromal dementia with Lewy bodies
Ian G. McKeith,Tanis J. Ferman,Alan J. Thomas,Frédéric Blanc,Bradley F Boeve,Hiroshige Fujishiro,Kejal Kantarci,Cristina Muscio,John T. O'Brien,Ronald B. Postuma,Dag Aarsland,Clive Ballard,Laura Bonanni,Paul C. Donaghy,Murat Emre,James E. Galvin,Douglas Galasko,Jennifer G. Goldman,Stephen N. Gomperts,Lawrence S. Honig,Manabu Ikeda,James B. Leverenz,Simon J.G. Lewis,Karen Marder,Mario Masellis,David P. Salmon,John-Paul Taylor,Debby W. Tsuang,Zuzana Walker,Pietro Tiraboschi +29 more
TL;DR: This work proposes operationalized diagnostic criteria for probable and possible mild cognitive impairment with Lewy bodies, which are intended for use in research settings pending validation for Use in clinical practice and are compatible with current criteria for other prodromal neurodegenerative disorders including Alzheimer and Parkinson disease.